Back to search results

Early Magnesium Sulfate for Moderate Asthma Attacks in Children

This study is looking at whether giving intravenous (IV) magnesium sulfate early to children aged 5-17 who come to the emergency department with a moderate asthma attack can help them get better faster. The study aims to see if early magnesium sulfate can reduce how long children stay in the emergency department or hospital, decrease the need for intensive care, or lessen the need for breathing support. Some children will receive IV magnesium sulfate within the first hour of treatment along with standard asthma care, while others will receive standard care without early magnesium sulfate. The main goal is to compare the length of hospital stay between these two groups.

Study design
This is an interventional study planning to enroll 100 participants. Participants will be randomly assigned to receive either IV magnesium sulfate or standard care, and the medical team will know which treatment each child receives.
What's involved
If you participate, you would receive either IV magnesium sulfate or standard care for your asthma attack. Your clinical progress, including length of stay and need for respiratory support, will be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Your length of stay will be measured from the start of treatment until discharge from the emergency department or admitting unit, up to one week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06137040

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

Recruiting
EARLY_PHASE1Ages 5–17InterventionalTreatment
University of Oklahoma
~100 participants
Updated 2024-12-06 on ClinicalTrials.gov
What's tested:Magnesium Sulfate within the first hourNo Magnesium sulfate within the first hour

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Length of Stay in Patients who receive IV Magnesium within the first hour (experimental group) vs control group
Measured over From initiation of therapy to discharge from the emergency department or admitting unit, up to 1 week

Conditions

Asthma in Children
Asthma Attack

Explore related trials

Asthma

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Ryan McKee, MD · PRINCIPAL_INVESTIGATOR · University of Oklahoma

Who to contact

Ryan McKee, MD
[email protected]
4056308997
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 5-17 years old
Presents to the ED with a respiratory score in the "Moderate" range (6
Parent(s)/Caregiver(s) speak English

Exclusion

Patients with chronic medical conditions including chronic pulmonary disease (other than asthma), cerebral palsy, congenital heart disease, tracheostomy dependent, myasthenia gravis patients
Patients who are pregnant
Parent(s)/Caregiver(s) do not speak English

What this trial measures

  • Change in Length of Stay in Patients who receive IV Magnesium within the first hour (experimental group) vs control groupFrom initiation of therapy to discharge from the emergency department or admitting unit, up to 1 week

    Evaluating whether timely administration of IV magnesium sulfate in moderate asthma exacerbations can reduce length of stay in the ED, general hospital bed or PICU. The data will also be analyzed to determine if more patients in the experimental group were able to be discharged from the emergency department compared to the control group.